Compounds > d-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene
Page last updated: 2024-12-06

d-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID98521
CHEBI ID166768
SCHEMBL ID3366383
MeSH IDM0040533

Synonyms (51)

Synonym
2446-23-3
(8r,9s,10r,13s,14s,17s)-4-chloro-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one
4-chloromethandienone
CHEBI:166768
4-chlorodehydromethyltestosterone
dehydrochloromethyltestosterone
oral turinabol
SCHEMBL3366383
unii-zpz473f40k
d-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene
4-chloro-methandienone
turinabol - oral
dehydrochlormethyltestosterone
turinabol-oral
androsta-1,4-dien-3-one, 4-chloro-17-hydroxy-17-methyl-, (17beta)-
zpz473f40k ,
oral-turinabol
4-chloro-17alpha-methyl-17beta-hydroxy-1,4-androstadiene-3-one
AM84830
4-chlorodianabol
4-chloro-1-dehydro-17-methyltestosterone
androsta-1,4-dien-3-one, 4-chloro-17-hydroxy-17-methyl-, (17.beta.)-
AGUNEISBPXQOPA-XMUHMHRVSA-N
4-chlordehydromethyltestosterone
dehydrochloromethyltestosterone, 4-chloro-17.beta.-hydroxy-17.alpha.-methyl-androst-1,4-dien-3-one
4-chloro-1-dehydromethyltestosterone
chlorodehydromethyltestosterone
chloroxymesterone
j507.800h ,
4-chloro-17.beta.-hydroxy-17.alpha.-methylandrost-1,4-dien-3-one
t-bol
chlorodehydromethyltestosterone [who-dd]
4-chloro-17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-androsta-1,4-dien-3-one
tbol
4-chloro-17.alpha.-methyl-17.beta.-hydroxyandrosta-1,4-dien-3-one
DTXSID10179216
(1s,2r,10r,11s,14s,15s)-6-chloro-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
4-chloro-17a-methyl-17b-hydroxy-1,4-androstadiene-3-one
4-chloro-17beta-hydroxy-17alpha-methylandrosta-1,4-dien-3-one
4-chloro-17b-hydroxy-17-methyl-androsta-1,4-dien-3-one
1-dehydro-4-chloro-17a-methyltestosterone
(17b)-4-chloro-17-hydroxy-17-methyl-androsta-1,4-dien-3-one
4-chloro-1,2-dehydro-17a-methyltestosterone
4-chloro-17a-methyl-17b-hydroxyandrosta-1,4-dien-3-one
1-dehydro-4-chloro-17-methyltestosterone
4-chloro-17b-hydroxy-17a-methyl-5a-androsta-1,4-dien-3-one
4-chloro-17a-methyl-andro-1,4-diene-3,17b-diol
BCP10777
Q909987
chlorodehydromethyl-testosterone, 1mg/ml in acetonitrile
chlorodehydromethyl-testosterone

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" From these data model independent pharmacokinetic parameters based on statistical moments were calculated."( [The pharmacokinetics of Oral-Turinabol in humans].
Schumann, W, 1991)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (52.38)18.7374
1990's3 (14.29)18.2507
2000's0 (0.00)29.6817
2010's3 (14.29)24.3611
2020's4 (19.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other17 (80.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
buformin
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.. buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.		1.9710biguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		1.9710aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		2.311017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		2.342017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
methandrostenolone
Methandrostenolone: A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188)		2.3520organic molecular entity
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		3.3611ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
turinabol
turinabol: RN given refers to (17beta)-isomer; do not confuse with related record for turinabol-oral		2.2510steroid ester
stanozolol
Stanozolol: A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194). stanozolol : An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes.		2.683017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		1.9610actinomycinmutagen
ConditionIndicatedRelationship StrengthStudiesTrials
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		03.7621
Acute Liver Injury, Drug-Induced
[description not available]		01.9610
Bile Duct Obstruction, Intrahepatic
[description not available]		01.9610
Age-Related Osteoporosis
[description not available]		01.9610
Peliosis Hepatis
A vascular disease of the LIVER characterized by the occurrence of multiple blood-filled CYSTS or cavities. The cysts are lined with ENDOTHELIAL CELLS; the cavities lined with hepatic parenchymal cells (HEPATOCYTES). Peliosis hepatis has been associated with use of anabolic steroids (ANABOLIC AGENTS) and certain drugs.		01.9610
Cholestasis, Intrahepatic
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).		01.9610
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		01.9610
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		01.9610
Leiomyosarcoma, Epithelioid
[description not available]		0210
Cancer of Testis
[description not available]		0210
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)		0210
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		0210
Complication, Postoperative
[description not available]		03.3611
Antithrombin 3 Deficiency
[description not available]		03.3611
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		03.3611
Antithrombin III Deficiency
An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.		03.3611
Hyperlipoproteinemia
[description not available]		01.9710
Hyperlipoproteinemias
Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.		01.9710